

# Danegaptide

Catalog No: tcsc1100



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg



## Specifications

**CAS No:**

943134-39-2

**Formula:**

$C_{14}H_{17}N_3O_4$

**Pathway:**

Cytoskeleton

**Target:**

Gap Junction Protein

**Purity / Grade:**

>98%

**Solubility:**

10 mM in DMSO

**Alternative Names:**

GAP-134;ZP 1609

**Observed Molecular Weight:**


291.3

## Product Description

Danegaptide (GAP-134), a small modified dipeptide, has been identified as a potent and selective second generation gap junction modifier with oral bioavailability.

IC50 & Target: Gap junction.

**In Vitro:** Gap junction uncoupling can alter conduction pathways and promote cardiac re-entry mechanisms that potentiate many supraventricular arrhythmias, such as atrial fibrillation (AF) and atrial flutter (AFL). Gap junction modifier Danegaptide (GAP-134), showed consistent efficacy on measures of conduction and AF/AFL inducibility in the canine sterile pericarditis model. Danegaptide (GAP-134) is a pharmacological agent with a favorable clinical safety profile and potential antiarrhythmic efficacy, as already confirmed in phase I clinical trials.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!